Oxurion NV Receives Transparency Notification from Atlas Special Opportunities II LLC

Oxurion NV, a biopharmaceutical company based in Leuven, Belgium, has announced the receipt of a transparency notification under Belgian law. The notification, received on July 18, 2025, was sent by Atlas Special Opportunities II, LLC. The content of this notification highlights that, as of July 16, 2025, Atlas holds 2,460,942 shares out of a total of 12,428,021 shares, thus falling below the 20% threshold due to the sale of voting securities.

The company's move falls in line with Belgian transparency legislation, ensuring shareholders and the market are informed of significant shareholding changes. This action reflects Oxurion's commitment to maintaining transparency in its financial and regulatory dealings.